unpopular opinion: most of what gets said here about glucagon is guesswork
unpopular opinion: most of what gets said here about glucagon is guesswork, and I am aware this is a minority view on this board.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
small trial, big effect, wide error bars
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Correction: TRIUMPH is the phase 3 programme.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Nothing containing this compound is approved anywhere.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
The constipation profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
phase 2 data only, and people quote it like it is a label
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
Is that the 48-week figure or an earlier readout?
Has anyone posted an independent test on this compound recently?
Which phase 2 arm are you quoting, and at what week?
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Read the phase 2 paper twice before ordering anything.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
a lot of the confident posting here is extrapolation
the energy-expenditure story is mechanistically interesting and clinically unproven
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
dose escalation in the trials was slow for a reason
research-use-only material is not approved for human use, full stop
the glucagon component is why the metabolic story reads differently
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
nothing here is available as a prescription product, so read every thread with that in mind
- 1The constipation profile felt different rather than worse. Hard to describe…8 comments in this branch · started by u/employer_carveout
- 2Phase 2 estimates effect and finds a dose range. Phase 3 estimates it…7 comments in this branch · started by u/cagrilintide_enthusiast